Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04742153

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Advanced or Metastatic Breast Cancer Clinical Trial

Official title:
A Multicenter, Non-randomized, Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Clinical Trial Summary

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-low locally advanced or metastatic BC.

Clinical Trial Description

The study will be conducted in two parts. The first part is efficacy exploration and the second part is efficacy verification. During the course of efficacy exploration, 33 subjects will be enrolled to preliminarily evaluate the safety and efficacy of MRG002. The second part will be adjusted according to the result of the first part. 29 subjects are planned to be enrolled. Considering the dropout rate of 10%, approximately 33 subjects are planned to be enrolled. A total of 66 subjects are planned to be enrolled in efficacy exploration and verification. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04742153
Study type Interventional
Source Shanghai Miracogen Inc.
Contact Program Director
Phone 86-21-61637960
Email clinicaltrials@miracogen.com.cn
Status Recruiting
Phase Phase 2
Start date May 13, 2021
Completion date February 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00748553 - A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase 1/Phase 2
Recruiting NCT05187832 - A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer Phase 1
Completed NCT01625286 - Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Phase 1/Phase 2
Terminated NCT05932667 - Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer Phase 2
Completed NCT05519059 - Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer Phase 1
Not yet recruiting NCT06201234 - Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Phase 2
Completed NCT02154776 - Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. Phase 1
Active, not recruiting NCT04494425 - Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Phase 3
Active, not recruiting NCT03767335 - MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer Phase 1
Recruiting NCT06105632 - A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Phase 3
Completed NCT01676753 - Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Phase 1
Active, not recruiting NCT01226316 - Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules Phase 1